Mark Studeny, MD
Cardiovascular Disease · Huntington, WVNPI 1326008517
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,126 of the $6,755 with a category attached, or 75.9%. 28 manufacturers reported payments, led by Abbott at 26.2% of the total. Reporting peaked in 2019 at $3,138 and has fallen 83.4% since, to $522 in 2025.
Across 160 payments — averaging $42.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boston Scientific$888
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$694
- Medtronic$630
- Edwards Lifesciences$563
- Abiomed$411
- plus $2K from 22 others
Across 1 payment — averaging $775.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$775
What the payments were for
- Travel & lodging$1,62924%
- Food & beverage$5,12676%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $1,768 |
| Boston Scientific | 19 | $888 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 34 | $694 |
| Medtronic(2 entities) | 6 | $630 |
| Edwards Lifesciences | 15 | $563 |
| Abiomed | 5 | $411 |
| AstraZeneca | 8 | $251 |
| Shockwave Medical, Inc | 3 | $218 |
| Novartis | 12 | $204 |
| Amgen | 14 | $163 |
| Inspire Medical Systems, Inc. | 1 | $138 |
| ZOLL Circulation Inc | 1 | $135 |
| Lantheus Medical Imaging, Inc. | 1 | $107 |
| Cvrx, Inc. | 3 | $85 |
| Celonova Biosciences, Inc. | 1 | $84 |
| Chiesi USA, Inc. | 5 | $71 |
| Pfizer | 5 | $64 |
| Angiodynamics, Inc. | 1 | $59 |
| Novo Nordisk | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 3 | $35 |
| Terumo Medical Corporation | 2 | $34 |
| Boehringer Ingelheim | 2 | $27 |
| Philips North America LLC | 1 | $20 |
| Cardiva Medical, Inc. | 1 | $17 |
| GE HealthCare | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Gilead | 1 | $12 |
| Penumbra, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xience V coronary stent system$1,305
- CoreValve Evolut$491
- AMPLATZER TALISMAN$149
- Impella$149
- Inspire$138
- TherOx DS2 Console$135
- Catheter$135
- Downstream Cartridge$135
- Vascular Lithotripsy$114
- AVVIGO Guidance System$113
- EMBLEM$112
- MitraClip System$107
- Definity$107
- SAPIEN 3 Ultra RESILIA$104
- LifeVest$102
How this compares
$6,755 in reported general payments places this provider in the 75th percentile of 100 cardiovascular disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $101,382 |
| XareltoRivaroxaban | 44 | $46,375 |
| Praluent PenAlirocumab | 15 | $10,825 |
| JardianceEmpagliflozin | 11 | $9,639 |
| Metoprolol Succinate | 175 | $2,378 |
| Labetalol Hcl | 31 | $2,320 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 156 | $2,070 |
| Losartan Potassium | 156 | $1,919 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 20 | $1,461 |
| ClopidogrelClopidogrel Bisulfate | 115 | $1,189 |
| Rosuvastatin Calcium | 140 | $1,188 |
| Atorvastatin Calcium | 118 | $1,060 |
| Warfarin Sodium | 64 | $802 |
| Potassium Chloride | 28 | $772 |
| Nitroglycerin | 71 | $750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $101,38288 claims |
| Johnson & JohnsonXarelto | $13 | $46,37544 claims |
| Boehringer IngelheimJardiance | $27 | $9,63911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 100 cardiovascular disease providers in West Virginia.
Other cardiovascular disease in Huntington
- Kofi OseiHuntington$87K
- Esam BaryunHuntington$55K
- Rameez SayyedHuntington$21K
- Jason MaderHuntington$13K
- Samian SulaimanHuntington$7K
- Ellen ThompsonHuntington$6K
- Amrit ThakurHuntington$5K
- Mehiar El-HamdaniHuntington$4K
- George LinsenmeyerHuntington$2K
- Sarah RinehartCharleston$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.